<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="173049">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00843310</url>
  </required_header>
  <id_info>
    <org_study_id>07-919</org_study_id>
    <secondary_id>Celgene # RV-MM-PI-289</secondary_id>
    <nct_id>NCT00843310</nct_id>
  </id_info>
  <brief_title>Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple Myeloma</brief_title>
  <official_title>Phase II Study of Revlimid (Lenalidomide), Melphalan, and Dexamethasone (ReMeDex) for Newly Diagnosed Multiple Myeloma Patients Not Undergoing Autologous Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>New York University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to determine whether addition of Revlimid to standard therapy will increase
      overall and complete response rates compared to historical standard frontline therapy and
      whether this combination treatment has fewer side effects than similar combination induction
      treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Current multiple myeloma therapies, typically an induction regimen followed by consolidation
      therapy with high dose chemotherapy and autologous stem cell rescue (autologous
      transplantation), can induce remission but relapse and death are inevitable. A growing body
      of literature suggests that consolidation therapy with autologous transplantation does not
      confer additional survival benefit and may have increased procedure-related morbidity and
      mortality in patients over 65 years old. Autologous transplantation is no longer recommended
      as standard care for this population. In addition, certain patients may not be eligible for
      autologous transplantation due to co-morbid medical conditions or may elect not to undergo
      the procedure for personal reasons.

      The historic standard of care for multiple myeloma patients who were not eligible for
      autologous transplantation for consolidation was induction therapy with melphalan/
      prednisone (MP), often followed by some form of maintenance therapy after achievement of
      complete or partial remission. A recent phase 3 study showed that the addition of
      thalidomide to MP (MPT) demonstrated higher overall and complete response rates. For
      patients who are eligible for autologous transplantation, thalidomide/ dexamethasone (Thal
      Dex) induction therapy is considered the standard of care, but a phase 2 study of
      lenalidomide (Revlimid)/ dexamethasone (Rev Dex) induction therapy demonstrated higher
      overall and complete response rates compared to Thal Dex. In addition, lenalidomide has a
      favorable side effect profile compared to thalidomide. Based on these data, we hypothesize
      that the combination of Revlimid/ melphalan/ dexamethasone (ReMeDex) induction therapy for
      myeloma patients who are not planned for autologous transplantation due to age restriction
      or other factors may demonstrate higher overall and/ or complete response rates with fewer
      side effects.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Due to slow accrual
  </why_stopped>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall and Complete Response Rates</measure>
    <time_frame>every 28 days during therapy and every month after therapy for 2 years</time_frame>
    <description>Response rate is defined as the percentage of patients who achieved response out of the total enrolled patients. Response is evaluated using the International Uniform Response Criteria by the International Myeloma Working Group.
Overall response = stringent complete response+complete response+very good partial response+partial response;
Complete response = stringent complete response+complete response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Drug Toxicity Rates</measure>
    <time_frame>during therapy and 30 days after</time_frame>
    <description>Percentage of participantswho experienced an adverse event among the treated population.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>every 28 days during therapy and every month after therapy for 2 years</time_frame>
    <description>Progression of disease is evaluated using the International Uniform Response Criteria by the International Myeloma Working Group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>every 28 days during therapy and every month after therapy for 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>ReMeDex</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide (Revlimid)</intervention_name>
    <arm_group_label>ReMeDex</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <arm_group_label>ReMeDex</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <arm_group_label>ReMeDex</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly Diagnosed multiple myeloma, ISS stage I-III requiring therapy: Serum M-protein
             ≥1 gm/dL (≥10 gm/L), Urine M-protein ≥200 mg/24 hr, Serum FLC assay: involved FLC ≥10
             mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal

          -  Previously untreated except prior treatment with corticosteroid less than one full
             cycle of pulsed dose dexamethasone (40 mg daily days 1-4, 9-12, and 17-20) or
             equivalent is allowed. Concomitant administration of IV bisphosphonates, Zometa
             (zoledronic acid, up to 4 mg IVSS over 30 minutes every four weeks) or Aredia
             (alendronate, up to 90 mg IVSS over 4 hours every four weeks), for prophylaxis
             against skeletal complications due to lytic bone disease or for acute management of
             hypercalcemia is allowed. Concomitant external beam radiation therapy for local
             management of lytic bone disease is allowed.

          -  Age ≥ 18 years old

          -  Life expectancy ≥ 12 weeks

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status will be employed. ECOG
             0-2 accepted.

          -  WBC ≥ 3.0 X 103/ µL, ANC ≥ 1.5 X 103/ µl, Hgb ≥ 8.0 gm/ dL, Plt ≥ 75 X 103/ µl, Serum
             Creatinine ≤ 2.0 mg/ dL

          -  Ability to understand and the willingness to sign a written informed consent
             document.

          -  All study participants must be registered into the mandatory RevAssist® program, and
             be willing and able to comply with the requirements of RevAssist®.

          -  Females of childbearing potential (FCBP) must have a negative serum or urine
             pregnancy test with a sensitivity of at least 50 mIU/mL within 10 - 14 days prior to
             and again within 24 hours of prescribing lenalidomide (prescriptions must be filled
             within 7 days) and must either commit to continued abstinence from heterosexual
             intercourse or begin TWO acceptable methods of birth control, one highly effective
             method and one additional effective method AT THE SAME TIME, at least 28 days before
             she starts taking lenalidomide. FCBP must also agree to ongoing pregnancy testing.
             Men must agree to use a latex condom during sexual contact with a FCBP even if they
             have had a successful vasectomy. See Appendix A: Risks of Fetal Exposure, Pregnancy
             Testing Guidelines and Acceptable Birth Control Methods.

          -  Able to take aspirin (81 or 325 mg) daily as prophylactic anticoagulation (patients
             intolerant to ASA may use warfarin or low molecular weight heparin).

        Exclusion Criteria:

          -  Prior therapy with Revlimid®, Thalomid (thalidomide), Velcade (bortezomib), Alkeran
             (melphalan) excluded. Prior therapy with corticosteroid allowed as defined in
             inclusion criteria.

          -  No prior or concurrent treatment with an investigational agent.

          -  Active Hepatitis B or C excluded, New York Heart Association grade III/IV congestive
             heart failure excluded, History of bleeding disorder excluded, History of platelet
             function disorder, History of deep vein thrombosis or other thromboembolic event
             excluded

          -  Prior history of allergic reaction to IMiD™ compounds (Thalidomide, Lenalidomide)
             excluded.

          -  Concomitant treatment with nonsteroidal antiinflammatory drugs (NSAIDs)(with the
             exception of aspirin) or other nephrotoxic agents is excluded.

          -  Serum creatinine &gt; 2.0 mg/ dL is excluded

          -  Pregnancy and breastfeeding excluded

          -  Known HIV+ patients are excluded.

          -  Other active hematologic or solid tumor or history of such disease requiring therapy
             of any form within five years of screening is excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hearn J Cho, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellevue Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Tisch Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 13, 2013</lastchanged_date>
  <firstreceived_date>February 12, 2009</firstreceived_date>
  <firstreceived_results_date>August 13, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>multiple myeloma</keyword>
  <keyword>frontline treatment</keyword>
  <keyword>first-line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone 21-phosphate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were enrolled from NYU medical center and its affiliated hospitals from Dec 2008 through Apr 2011.</recruitment_details>
      <pre_assignment_details>Total 8 patients were enrolled. One patient withdrew before the treatment started.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ReMeDex</title>
          <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ReMeDex</title>
          <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69" lower_limit="67" upper_limit="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>paticipants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall and Complete Response Rates</title>
        <description>Response rate is defined as the percentage of patients who achieved response out of the total enrolled patients. Response is evaluated using the International Uniform Response Criteria by the International Myeloma Working Group.
Overall response = stringent complete response+complete response+very good partial response+partial response;
Complete response = stringent complete response+complete response</description>
        <time_frame>every 28 days during therapy and every month after therapy for 2 years</time_frame>
        <population>The study was terminated due to slow accrual and PI leaving the institution (8 participants vs. 37 target accrual). No data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>ReMeDex</title>
            <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall and Complete Response Rates</title>
          <description>Response rate is defined as the percentage of patients who achieved response out of the total enrolled patients. Response is evaluated using the International Uniform Response Criteria by the International Myeloma Working Group.
Overall response = stringent complete response+complete response+very good partial response+partial response;
Complete response = stringent complete response+complete response</description>
          <population>The study was terminated due to slow accrual and PI leaving the institution (8 participants vs. 37 target accrual). No data were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Toxicity Rates</title>
        <description>Percentage of participantswho experienced an adverse event among the treated population.</description>
        <time_frame>during therapy and 30 days after</time_frame>
        <population>Please see the reports on AEs and SAEs in next section.</population>
        <group_list>
          <group group_id="O1">
            <title>ReMeDex</title>
            <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Toxicity Rates</title>
          <description>Percentage of participantswho experienced an adverse event among the treated population.</description>
          <population>Please see the reports on AEs and SAEs in next section.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression</title>
        <description>Progression of disease is evaluated using the International Uniform Response Criteria by the International Myeloma Working Group.</description>
        <time_frame>every 28 days during therapy and every month after therapy for 2 years</time_frame>
        <population>The study was terminated due to slow accrual and PI leaving the institution (8 participants vs. 37 target accrual). No data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>ReMeDex</title>
            <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression</title>
          <description>Progression of disease is evaluated using the International Uniform Response Criteria by the International Myeloma Working Group.</description>
          <population>The study was terminated due to slow accrual and PI leaving the institution (8 participants vs. 37 target accrual). No data were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival</title>
        <time_frame>every 28 days during therapy and every month after therapy for 2 years</time_frame>
        <population>The study was terminated due to slow accrual and PI leaving the institution (8 participants vs. 37 target accrual). No data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>ReMeDex</title>
            <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival</title>
          <population>The study was terminated due to slow accrual and PI leaving the institution (8 participants vs. 37 target accrual). No data were analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Only 7 out of 8 patients were treated. The percentage of affected patients was based on those 7.</desc>
      <group_list>
        <group group_id="E1">
          <title>ReMeDex</title>
          <description>Treatment phase (28 days/cycle x 6 cycles):
Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22.
Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase):
lenalidomide: 10 mg/day orally on days 1-21 followed by 7 days of rest (28 days/cycle) for a maximum of 24 cycles.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain-back</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain or cramping</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia, esophagitis, odynophagia (painful swallowing)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Constitutional Symptoms-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelets</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypocalcemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal-Other</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary frequency/urgency</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bruising (in absence of grade 3 or 4 thrombocytopenia)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dermatology/Skin-Other</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Hearn J. Cho, MD</name_or_title>
      <organization>NYU Cancer Institute</organization>
      <phone>212-263-9274</phone>
      <email>hearn.jay.cho@med.nyu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
